erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the .
andrew kaye, head of policy at macmillan cancer support said it was �shocking� that a cancer patient had to wait 541 days for treatment. .